PatentJun 25, 2026, 08:01 AM
Incannex Receives US Patent for IHL-42X in Obstructive Sleep Apnea
AI Summary
Incannex Healthcare Inc. announced that the United States Patent and Trademark Office (USPTO) has granted a key patent for its IHL-42X composition and methods of treatment for Obstructive Sleep Apnea (OSA). This patent, with a baseline expiry of July 9, 2040, significantly strengthens the company's intellectual property portfolio and enhances the commercial value of IHL-42X. The company is also nearing commencement of patient recruitment for its DReAMzz Phase 2 dose optimization study, further advancing the clinical development of IHL-42X.
Key Highlights
- USPTO granted patent "Compositions and Methods of Treatment for Obstructive Sleep Apnea" for IHL-42X.
- The patent covers the proprietary IHL-42X composition and therapeutic methods for Obstructive Sleep Apnea (OSA).
- The patent has a baseline expiry date of July 9, 2040.
- Incannex is exploring eligibility for patent term extension following potential FDA approval.
- The patent significantly strengthens Incannex's intellectual property portfolio for its lead clinical program.
- IHL-42X has FDA Fast Track designation and positive Phase II clinical data.
- Patient recruitment for the DReAMzz Phase 2 dose optimization study is nearing commencement.
Price Impact
More from IXHL